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Background
Secondary bacterial infections following viral infections of
the airways are well documented and are associated with
increased severity of respiratory disease compared to virus
or bacterial infections alone. Human rhinovirus (HRV)
infections are the most common causes of exacerbations
in individuals with chronic airways diseases such as
asthma and COPD. Moreover, bacterial colonization is
commonly found in the airways of patients experiencing
exacerbations of these chronic airways diseases and linked
to increased severity and duration of these exacerbations.
The mechanisms underlying the increased prevalence of
secondary bacterial infections and the association with
more severe outcomes following viral infections is not
known. It has been suggested that viral infection of the
airways cause dysregulation of innate host defense
mechanisms, such as, impaired antimicrobial peptide
expression of the airways. Antimicrobial peptides are key
components of the innate immune response after infection
and are important in efficient clearance of microbial colo-
nization to prevent infection. We sought to determine
whether HRV modulates the innate host defense response
to secondary bacterial infections of the airways.
Methods
Studies performed using primary human bronchial epithe-
lial cells (HBECs). Cells grown in monolayer to confluence
(80-90%). Antibiotics and Hydrocortisone were removed
from the media 48 h and 24 h prior to infection respec-
tively. On day of infection, cells were stimulated with puri-
fied HRV-16 or bacteria (H. influenzae/P. aeruginosa)
alone, or treated in combination of HRV-16 then subse-
quently bacteria. TLR5 agonists (Flagella) also used alone
and in combination with HRV-16. The protein and
mRNA levels of different antimicrobial peptides
(b-defensin, LL-37, lysozyme, lactoferrin, and SLPI)
measured using ELISA (R&D Systems) and real-time
RT-PCR (Applied Biosystems), respectively.
Results
Preliminary data indicate supernatants from HRV-16/
bacterial co-infection resulted in synergistic trend in
b-defensin levels compared to HRV and bacteria alone.
A synergistic increase in b-defensin levels was also seen
with TLR5 agonist when combined post HRV-16 infec-
tion compared to TLR5 or HRV-16 alone. Minimum
inhibitory concentration results showed b-defensin
(1mg/ml), Lysozyme (30µg/ml), Lactoferrin (1mg/ml)
and LL-37 (460µg/ml) were able to inhibit growth of
NTHi and PAO.
Conclusions
The data provide the first demonstration that there is a
dysregulation of antimicrobial levels in HRV infected
HBECs when encountered with a secondary bacterial
infection. This provides evidence to why individuals with
chronic airways diseases have a prolonged and more
severe disease state than normal individuals. It could also
lead to a new targeted therapy of people with diseases
such as asthma or COPD to decrease severity of
exacerbations.
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